JONES PHARMA INC
15-12G, 2000-08-31
PHARMACEUTICAL PREPARATIONS
Previous: NOVA NATURAL RESOURCES CORP, 8-K, 2000-08-31
Next: PILGRIM GLOBAL INCOME FUND, N-30D, 2000-08-31



<PAGE>   1

                      SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C. 20549


                                   FORM 15


  Certification and Notice of Termination of Registration under Section 12(g)
        of the Securities Exchange Act of 1934 or Suspension of Duty to
           File Reports Under Section 13 and 15(d) of the Securities
                              Exchange Act of 1934


                          Commission File No. 0-15098

                           JONES PHARMA INCORPORATED
--------------------------------------------------------------------------------
            (Exact name of registrant as specified in its charter)


                      1945 Craig Road, St. Louis, MO 63146
                                 (314) 576-6100
--------------------------------------------------------------------------------
         (Address, including zip code and telephone number, including
           area code, of registrant's principal executive offices)

                     Common Stock, par value $.04 per share
--------------------------------------------------------------------------------
           (Title of each class of securities covered by this Form)

                                      None
--------------------------------------------------------------------------------
          (Titles of all other classes of securities for which a duty
            to file reports under section 13(a) or 15(d) remains)


        Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:

     Rule 12g-4(a)(1)(i)    [X]        Rule 12h-3(b)(1)(ii)     [ ]
     Rule 12g-4(a)(1)(ii)   [ ]        Rule 12h-3(b)(2)(i)      [ ]
     Rule 12g-4(a)(2)(i)    [ ]        Rule 12h-3(b)(2)(ii)     [ ]
     Rule 12g-4(a)(2)(ii)   [ ]        Rule 15d-6               [ ]
     Rule 12h-3(b)(1)(i)    [ ]

        Approximate number of holders of record as of the certification or
notice date: None (issuer was merged into King Pharmaceuticals, Inc.)

        Pursuant to the requirements of the Securities Exchange Act of 1934,
Jones Pharma Incorporated has caused this certification/notice to be
signed on its behalf by the undersigned duly authorized person.


Dated:  August 31, 2000               By: /s/ John A. A. Bellamy
        -----------------                 -------------------------------
                                          John A. A. Bellamy
                                          Executive Vice President, Legal
                                          Affairs and General Counsel

Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 of the
General Rules and Regulation under the Securities Exchange Act of 1934. The
registrant shall file with the Commission three (3) copies of Form 15, one of
which shall be manually signed. It may be signed by an officer of the
registrant, by counsel or by any other duly authorized person. The name and
title of the person signing the form shall be typed or printed under the
signature



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission